174 related articles for article (PubMed ID: 34061764)
1. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
de Mestier L; Lamarca A; Hernando J; Zandee W; Alonso-Gordoa T; Perrier M; Walenkamp AM; Chakrabarty B; Landolfi S; Van Velthuysen MF; Kats-Ugurlu G; Caminoa A; Ronot M; Manoharan P; Garcia-Alvarez A; Brabander T; García Gómez-Muriel MI; Cadiot G; Couvelard A; Capdevila J; Pavel ME; Cros J
Endocr Relat Cancer; 2021 Jun; 28(8):549-561. PubMed ID: 34061764
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Merola E; Alonso Gordoa T; Zhang P; Al-Toubah T; Pellè E; Kolasińska-Ćwikła A; Zandee W; Laskaratos F; de Mestier L; Lamarca A; Hernando J; Cwikla J; Strosberg J; de Herder W; Caplin M; Cives M; van Leeuwaarde R
Oncologist; 2021 Apr; 26(4):294-301. PubMed ID: 33301235
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
4. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Ali AS; Grönberg M; Langer SW; Ladekarl M; Hjortland GO; Vestermark LW; Österlund P; Welin S; Grønbæk H; Knigge U; Sorbye H; Janson ET
Med Oncol; 2018 Mar; 35(4):47. PubMed ID: 29511910
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
[TBL] [Abstract][Full Text] [Related]
6. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
8. Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Boutin M; Mathews A; Badesha J; Paul A; Safro M; Gill S; Stuart HC; Schaeffer D; Farnell D; Loree JM
Pancreas; 2022 Aug; 51(7):756-762. PubMed ID: 36395400
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors.
Girot P; Baudin E; Senellart H; Bouarioua N; Hentic O; Guimbaud R; Walter T; Ferru A; Roquin G; Cadiot G; Pracht M; Girot JB; Malka D; Ducreux M; Bennouna J; Matysiak-Budnik T; Hadoux J; Touchefeu Y
Neuroendocrinology; 2022; 112(6):537-546. PubMed ID: 34348346
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.
Liu AJ; Ueberroth BE; McGarrah PW; Buckner Petty SA; Kendi AT; Starr J; Hobday TJ; Halfdanarson TR; Sonbol MB
Oncologist; 2021 May; 26(5):383-388. PubMed ID: 33496040
[TBL] [Abstract][Full Text] [Related]
12. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Pavel M; Ćwikła JB; Lombard-Bohas C; Borbath I; Shah T; Pape UF; Capdevila J; Panzuto F; Truong Thanh XM; Houchard A; Ruszniewski P
Eur J Cancer; 2021 Nov; 157():403-414. PubMed ID: 34597974
[TBL] [Abstract][Full Text] [Related]
14. The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
Guan Y; Yao Q; Hao Y; Zeng X; Wang W; Gu X; Xiang J; Sun Y; Song Z
Cancer Med; 2023 Aug; 12(15):16011-16018. PubMed ID: 37351565
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Roquin G; Baudin E; Lombard-Bohas C; Cadiot G; Dominguez S; Guimbaud R; Niccoli P; Legoux JL; Mitry E; Rohmer V; Ruszniewski P; Walter T; Ducreux M; Couvelard A; Scoazec JY; Ramond-Roquin A; Caroli-Bosc FX; Hentic O
Neuroendocrinology; 2018; 106(1):38-46. PubMed ID: 28152531
[TBL] [Abstract][Full Text] [Related]
16. Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; Colao A; Falconi M; Delle Fave G
Oncologist; 2014 Sep; 19(9):966-74. PubMed ID: 25117065
[TBL] [Abstract][Full Text] [Related]
17. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
18. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E; Karaca H; Koca S; Sevinç A; Hacioğlu B; Özkan M; Özçelik M; Duran AO; Hacibekiroğlu İ; Yildiz Y; Tanriverdi Ö; Menekşe S; Aksoy A; Bozkurt O; Urvay S; Uysal M; Demir H; Çiltaş A; Dane F
Anticancer Drugs; 2017 Feb; 28(2):222-229. PubMed ID: 27768606
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors.
Spada F; Antonuzzo L; Marconcini R; Radice D; Antonuzzo A; Ricci S; Di Costanzo F; Fontana A; Gelsomino F; Luppi G; Nobili E; Galdy S; Cella CA; Sonzogni A; Pisa E; Barberis M; Fazio N
Neuroendocrinology; 2016; 103(6):806-14. PubMed ID: 26789262
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
